FDA Approved: CANCIDAS — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for CANCIDAS (caspofungin acetate) from Merck Sharp & Dohme LLC, authorizing changes to the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia
• Esophageal Candidiasis
• Invasive Candidiasis

Drugs mentioned

• Cancidas (caspofungin)

Snippet

SUPPL AP for CANCIDAS (CASPOFUNGIN ACETATE)